Quantcast

Industry news that matters to you.  Learn more

Gentris Corporation Launches Next Generation Human Transcriptome Array

Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, recently announced that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip(R) Human Transcriptome Array (HTA) services. The GeneChip(R) HTA is a high resolution microarray for gene expression that is designed to empower next-generation expression profiling studies. The new array goes beyond gene-level expression profiling by providing the coverage and accuracy required to detect all known transcript isoforms produced by a gene.

bioTheranostics To Present Data on CancerTYPE ID and Breast Cancer Index at 2013 ASCO Annual Meeting

bioTheranostics, Inc., a leading provider of molecular diagnostic solutions for cancer, recently announced that 11 data presentations will be released during the American Society of Clinical Oncology (ASCO) annual meeting May 31–June 4, 2013, in Chicago. The studies highlight the clinical utility of the company’s CancerTYPE ID® assay and Breast Cancer IndexSM (BCI), with results supporting the role of these molecular tests in individualized treatment programs for cancer patients.

bioTheranostics also will host an Industry Expert Theater educational presentation titled, “Demanding Certainty in Metastatic Cancer Diagnosis: The Clinical Impact of
CancerTYPE ID®,” June 2, 2013, at 11:30 a.m. The company’s products will be demonstrated at booth #23041.

“These studies are part of a large and growing body of clinical evidence demonstrating the positive impact our CancerTYPE ID and Breast Cancer Index molecular tests have on the management of cancer patients,” said Richard Ding, president and CEO of bioTheranostics. “The data provide key insights into the value of our molecular tests in influencing clinical decision making and impacting patient outcomes and healthcare costs, and we look forward to sharing and discussing the results during the 2013 ASCO meeting.”

The studies were conducted by researchers at leading institutions, including Linköping University (Sweden); Louisiana State University Health Sciences Center; Massachusetts General Hospital; Sarah Cannon Research Institute; University of California, San Francisco, School of Medicine; University of Kentucky; University of Pittsburgh Medical Center; and the University of Texas MD Anderson Cancer Center.

CancerTYPE ID Posters & Abstracts

  • Poster presentation: Molecular tumor profiling (MTP) of poorly differentiated neoplasms (PDN) of unknown primary site. Greco FA, et al. Abstract #11080.
  • Multivariate analysis of prognostic factors in cancer of unknown primary (CUP) patients treated with site-specific therapy based on the 92-gene cancer classifier. Schnabel CA,
    et al. Abstract #e15006.
  • Impact of the 92-gene assay on cost of diagnosis of tumor type in metastatic cancer of uncertain origin. Bentley TG, et al. Abstract #e15104.
  • Effect of the 92-gene molecular classifier on therapeutic decision-making in cancers of uncertain primary. Schroeder B, et al. Abstract #e15130.
  • Use of the 92-gene assay to identify tumor type and direct predictive biomarker testing in limited tissue specimens. Operana TN, et al. Abstract #e19072.
  • Poster presentation: Diagnostic utility and prognostic performance of a 92-gene cancer classifier to molecularly profile periampullary adenocarcinomas (PAA). Overman MJ, et al. Abstract #4133.
  • Renal cell carcinoma (RCC) presenting as cancer of unknown primary (CUP): Diagnosis by molecular tumor profiling (MTP). Hainsworth JD, et al. Abstract #e15501.
  • Poster presentation: Gene expression profiling (GEP) to predict the primary site of metastatic neuroendocrine tumors (NETs) presenting with an unknown primary. Woltering E, et al. Abstract #4141.
  • Confirmation of non-small cell lung cancer (NSCLC) diagnosis using ALK testing and genetic profiling in patients presenting with carcinoma of unknown primary site (CUP). Penley WC, et al. Abstract #e19062.

Breast Cancer Index Poster & Abstract

  • Poster presentation: Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index. Zhang Y, et al. Abstract #594.
  • Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer. Gustavsen G, et al. Abstract #e11504.

Abstracts for the 11 studies concerning bioTheranostics’ molecular tests can be accessed on the ASCO website.

Source: bioTheranostics

Scientists Decode ‘Software’ Instructions of Aggressive Leukemia Cells

A team of national and international researchers, led by Weill Cornell Medical College scientists, have decoded the key “software” instructions that drive three of the most virulent forms of acute lymphoblastic leukemia (ALL). They discovered ALL’s “software” is encoded with epigenetic marks, chemical modifications of DNA and surrounding proteins, allowing the research team to identify new potential biomarkers and therapeutic targets.

Affymetrix Launches Advanced RNA Amplification Technology for Whole-Genome Expression Analysis of FFPE Samples

Affymetrix, Inc. (NASDAQ:AFFX) announced today the availability of SensationPlus™ FFPE Amplification and 3’ IVT Labeling Kit (SensationPlus™ FFPE Reagent Kit), consisting of RNA amplification and labeling modules, to enable gene expression profiling of formalin-fixed, paraffin-embedded (FFPE) samples on GeneChip® 3’ IVT arrays and Almac XcelTM Array for disease clinical research and retrospective studies.

Plexpress Oy and Phalanx Biotech Group Offer Biomarker Discovery and Validation Service

Plexpress Oy, the creator of the innovative TRAC platform for high-throughput gene expression analysis, and Phalanx Biotech Group, the original design manufacturer of the OneArray line of high-quality microarrays for gene expression and microRNA profiling, have established a strategic alliance to offer the OneTRAC service. The new service package will allow researchers to not only discover and select genomic biomarkers, but also to fully validate and understand their function in a streamlined, integrated workflow. The OneTRAC analysis service will be offered by Plexpress in Europe, and by Phalanx Biotech in the United States and Asia.